meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
A EFFACER BBV152 (Bharat Biotech, India)
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)
A EFFACER_ Vero cell
A EFFACER_sequential Immunization
BCG vaccination
complete primary vaccine series
CoVLP (MT-2766, Medicago)
DNA vaccine
bacTRL-Spike
Zy-Cov-D (Zydus Cadila)
ebola vaccine
first booster dose
mRNA vaccine (any) - first boost
Comirnaty - first boost
Spikevax - first boost
Non replicating viral vector -first boost
Janssen AD26 vaccine - fisrt boost
Vaxzevria -first boost
heterologous prime-boost
Inactivated virus vaccine
CoronaVac (SinoVac)
Covaxin, Bharat Biotech (BBV152)
Shifa-Pharmed inactivated vaccine
Sinopharm Beijing (BBIBP-CorV)
Sinopharm Wuhan
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
CureVac
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus)
Ad26.ZEBOV ()
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine)
CanSino (Convidecia)
Covishield (Oxford/AZ formulation)
Janssen AD26 vaccine (JNJ-78436735)
Sputnik V (Gam-COVID-Vac)
SPUTNIK-LIGHT
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
protein subunit vaccine
Anhui Zhifei Longcom
CoVax-19 SpikoGen
Nuvaxovid (NVX-CoV2373) Novavax
Sanofi/GSK recombinant protein vaccine
SCB-2019
Replicating Viral Vector
seasonal influenza vaccines
second booster dose
mRNA vaccine (any) - second boost
Comirnaty - second boost
Spikevax - second boost
virus-like particles vaccine
Medicago
Vitamins
potential COVID-19 treatments
control
placebo
uncontrolled study
vaccines
complete primary vaccine series
first booster dose
mRNA vaccine (any) - first boost
Comirnaty - first boost
Inactivated virus vaccine
CoronaVac (SinoVac)
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
Non replicating viral vector
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
adolescents (typically 12-15 years of age)
adults (typically between 18 and 65yr)
age >= 55 yr
age >= 60 yr
age >= 65 yr
age >= 75 yr
alpha variant (B.1.1.7, UK)
any cancer
autoimmune disease
beta variant (B.1.351 / 501Y.V2, South Africa)
children
delta variant (B.1.617.2, Indian)
dialysis patients
elderly (typically over 65yr)
fully vaccinated
gamma variant (P.1, Brazil)
haematological cancers
healthcare workers
immunodepression
kidney transplant recipients
obese
omicron variant BA.1 (B.1.1.529)
omicron variant BA.2 VOC
original (Wuhan) strain
positive for SARS-Cov-2 at baseline
solid cancer
solid organ transplant recipients
subjects at risk
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded